SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Description
The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among